Navigation Links
Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
Date:2/15/2012

PRINCETON, N.J., Feb. 15, 2012 /PRNewswire/ --  Omthera Pharmaceuticals, Inc., a privately held emerging specialty pharmaceuticals company, announced today that Jerry Wisler, President and Chief Executive Officer, will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 3:20 p.m. EST.  He will also present at the Citi Global Healthcare Conference on February 29, 2012 at 11:00 a.m. EST.  Both conferences will be held at the Waldorf Astoria Hotel, New York, NY.

About Omthera Pharmaceuticals, Inc.
Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately held, emerging specialty pharmaceutical company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. In March 2011, the Company initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL).  In August 2011, Omthera initiated a Phase III trial for Epanova in patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss company. For more information, please visit www.omthera.com.

 

Omthera Contact:

Christian Schade

Chief Financial Officer

Omthera Pharmaceuticals

908-741-6402

CSchade@Omthera.com

 

Omthe
'/>"/>


SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
2. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
4. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
5. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
6. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
7. Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
8. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
9. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
10. Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality
11. Omthera Pharmaceuticals, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Potential New Approach for the Treatment of Inflammatory ... ... Million Payment from Partner GlaxoSmithKline, MOUNTAIN VIEW, Calif., May 13 ... trial of CCX354, an,orally-available, novel small molecule compound designed to specifically,target ...
... FRANCISCO, Calif., May 12 Napo,Pharmaceuticals, Inc., (LSE: ... in collaboration with QualityMetric, Inc. describing the development,of ... Health-Related,Quality of Life (HR-QoL) aspects of chronic diarrhea ... Society for Pharmacoeconomics and,Outcomes Research (ISPOR) Annual Meeting ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Napo Presents at ISPOR Meeting in Toronto 2
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... is Hepatitis Awareness Month, HARRISBURG, Pa., May 19 ... discussed the importance of,Hepatitis disease awareness and vaccination during ... individuals are considered at high risk for Hepatitis B ... care insurance or ready,access to medical care," said Dr. ...
... Insurance among 52 Companies Recognized for Promoting Healthy ... ... The National Business Group on,Health, a national non-profit organization of ... promoting a,healthy workplace and encouraging a healthy lifestyle for its employees ...
... reliable genetic tests to guide lung cancer treatment has ... evaluated the ability of five high-risk genetic profiles, or ... in patients whose non-small cell lung cancer was caught ... at the American Thoracic Societys 2008 International Conference in ...
... Saliva Diagnostics and Dental ... Dental Care, WASHINGTON, May 19 The American Academy ... is,holding its 61st Annual Session this week in Washington, D.C. ... discuss the latest,advancements and research in pediatric oral health., ...
... May 19 On May 13, 2008, the Cancer,Prevention ... the FDA. This updates scientific information detailed in a,November ... FDA. It also,documents prior knowledge of the FDA and ... scientific basis of the 2008 Petition is detailed in ...
... CHATTANOOGA, Tenn., May 19 Shared Health, Inc., ... (HIE), and,Novo Innovations, the leading healthcare provider of ... to provide,improved data integration delivered to clinicians at ... deploying Novo agent software to enhance the clinical,interface ...
Cached Medicine News:Health News:PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors 2Health News:National Business Group on Health Honors Erie Insurance As One of Best Employers for Healthy Lifestyles 2Health News:National Business Group on Health Honors Erie Insurance As One of Best Employers for Healthy Lifestyles 3Health News:Will lung cancer recur? A genetic test may provide the answer 2Health News:2008 American Academy of Pediatric Dentistry Annual Session Highlights Emerging Scientific Advancements 2Health News:2008 American Academy of Pediatric Dentistry Annual Session Highlights Emerging Scientific Advancements 3Health News:Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products 2Health News:Shared Health(R) and Novo Innovations Partner for Improved Information-Sharing of Clinical Health Records 2Health News:Shared Health(R) and Novo Innovations Partner for Improved Information-Sharing of Clinical Health Records 3
... Thermovent® T helps provide protection to the exposed ... and extremely lightweight making it ideal for active ... high rate of heat and moisture recovery, it ... ,All HMEs and filters have ISO standard tapered ...
... viscosity and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry ... 20-200 ... 1.0~2.0 Imprecision(%) ... 1 Dimensions: ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
Inquire...
Medicine Products: